
A pivotal time for an RNA pioneer
It’s a pivotal year for RNA therapeutics pioneer Ionis Pharmaceuticals.
After transitioning from a partnering model to a full-ownership strategy following the 2024 approval of Tryngolza, the company is expecting an FDA decision to expand the drug into severe hypertriglyceridemia as its first non-rare-disease indication for a wholly owned product. Meanwhile, potentially game-changing phase 3 readouts are expected from Ionis’ Novartis-partnered lipoprotein(a) candidate and AstraZeneca-partnered ATTR cardiomyopathy program.
In this week’s episode of "The Top Line,"…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.